Market Closed -
Euronext Amsterdam
09:05:00 26/04/2024 pm IST
|
5-day change
|
1st Jan Change
|
0.9
EUR
|
+2.16%
|
|
+2.16%
|
-12.71%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
989.6
|
811.6
|
502.8
|
707.2
|
690.2
|
606.1
|
-
|
-
|
Enterprise Value (EV)
1 |
975.2
|
765.7
|
457.1
|
637.6
|
619.7
|
515.2
|
486.7
|
454.6
|
P/E ratio
|
29
x
|
26.5
x
|
37.1
x
|
-
|
-74.7
x
|
-300
x
|
40.9
x
|
10.6
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
5.85
x
|
4.37
x
|
2.78
x
|
3.62
x
|
3.08
x
|
2.31
x
|
2.02
x
|
1.76
x
|
EV / Revenue
|
5.77
x
|
4.12
x
|
2.53
x
|
3.27
x
|
2.76
x
|
1.97
x
|
1.62
x
|
1.32
x
|
EV / EBITDA
|
14.8
x
|
10.1
x
|
8.9
x
|
21.4
x
|
64.4
x
|
50.8
x
|
16
x
|
6.56
x
|
EV / FCF
|
24.1
x
|
12.4
x
|
21.5
x
|
24.4
x
|
-35.9
x
|
20.8
x
|
14.6
x
|
7.9
x
|
FCF Yield
|
4.14%
|
8.09%
|
4.66%
|
4.1%
|
-2.78%
|
4.8%
|
6.87%
|
12.7%
|
Price to Book
|
9.45
x
|
5.55
x
|
-
|
-
|
3.44
x
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
6,31,323
|
6,38,056
|
6,48,749
|
6,52,414
|
6,69,406
|
6,73,438
|
-
|
-
|
Reference price
2 |
1.568
|
1.272
|
0.7750
|
1.084
|
1.031
|
0.9000
|
0.9000
|
0.9000
|
Announcement Date
|
05/03/20
|
04/03/21
|
17/03/22
|
16/03/23
|
14/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
169
|
185.7
|
180.7
|
195.1
|
224.1
|
262
|
300.5
|
344.7
|
EBITDA
1 |
66.08
|
75.74
|
51.35
|
29.82
|
9.629
|
10.15
|
30.44
|
69.28
|
EBIT
1 |
60.91
|
67.42
|
33.53
|
17.3
|
-4.922
|
-7.146
|
6.472
|
38.22
|
Operating Margin
|
36.03%
|
36.31%
|
18.55%
|
8.87%
|
-2.2%
|
-2.73%
|
2.15%
|
11.09%
|
Earnings before Tax (EBT)
1 |
46.68
|
39.27
|
20.97
|
14.22
|
-10.98
|
3.446
|
18.95
|
51.94
|
Net income
1 |
36.2
|
32.65
|
14.54
|
12.98
|
-9.246
|
1.335
|
14.11
|
41.26
|
Net margin
|
21.41%
|
17.58%
|
8.04%
|
6.65%
|
-4.12%
|
0.51%
|
4.7%
|
11.97%
|
EPS
2 |
0.0540
|
0.0480
|
0.0209
|
-
|
-0.0138
|
-0.003000
|
0.0220
|
0.0850
|
Free Cash Flow
1 |
40.38
|
61.96
|
21.29
|
26.17
|
-17.25
|
24.75
|
33.42
|
57.53
|
FCF margin
|
23.89%
|
33.37%
|
11.78%
|
13.41%
|
-7.7%
|
9.44%
|
11.12%
|
16.69%
|
FCF Conversion (EBITDA)
|
61.11%
|
81.82%
|
41.45%
|
87.76%
|
-
|
243.85%
|
109.81%
|
83.04%
|
FCF Conversion (Net income)
|
111.57%
|
189.76%
|
146.44%
|
201.67%
|
-
|
1,854.09%
|
236.82%
|
139.43%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
05/03/20
|
04/03/21
|
17/03/22
|
16/03/23
|
14/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2021 S1
|
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 S1
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
88.59
|
78.74
|
45.62
|
62.43
|
44.22
|
49.02
|
94.59
|
53.87
|
51.84
|
38.75
|
50.2
|
89.1
|
63
|
74.19
|
64.27
|
66.1
|
-
|
66.1
|
66.23
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-
|
9.74
|
7.613
|
-
|
17.42
|
-
|
7.712
|
-9.658
|
-12.45
|
4.845
|
-
|
1.795
|
1.005
|
1.882
|
-1.992
|
-
|
54.93
|
-70.73
|
Operating Margin
|
-
|
-
|
21.35%
|
12.19%
|
-
|
35.54%
|
-
|
14.31%
|
-18.63%
|
-32.12%
|
9.65%
|
-
|
2.85%
|
1.35%
|
2.93%
|
-3.01%
|
-
|
83.1%
|
-106.79%
|
Earnings before Tax (EBT)
1 |
25.9
|
16.91
|
1.14
|
3.583
|
4.015
|
19.12
|
23.25
|
9.217
|
-17.16
|
-15.19
|
3.096
|
-12.15
|
3.117
|
-1.827
|
6.852
|
5.373
|
22.03
|
29.76
|
-35.66
|
Net income
1 |
18.14
|
12.12
|
-0.3616
|
3.213
|
3.283
|
15.35
|
18.77
|
9.04
|
-13.88
|
-11.12
|
1.206
|
-9.957
|
3.306
|
-2.467
|
6.026
|
4.547
|
18.73
|
28.89
|
-36.54
|
Net margin
|
20.48%
|
15.39%
|
-0.79%
|
5.15%
|
7.42%
|
31.31%
|
19.85%
|
16.78%
|
-26.78%
|
-28.7%
|
2.4%
|
-11.18%
|
5.25%
|
-3.33%
|
9.38%
|
6.88%
|
-
|
43.7%
|
-55.16%
|
EPS
|
0.0250
|
0.0160
|
-0.000860
|
-
|
-
|
-
|
-
|
0.0129
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/07/20
|
05/08/21
|
28/10/21
|
17/03/22
|
12/05/22
|
04/08/22
|
04/08/22
|
27/10/22
|
16/03/23
|
11/05/23
|
03/08/23
|
03/08/23
|
26/10/23
|
14/03/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
14.4
|
46
|
45.6
|
69.7
|
70.5
|
90.9
|
119
|
151
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
40.4
|
62
|
21.3
|
26.2
|
-17.3
|
24.7
|
33.4
|
57.5
|
ROE (net income / shareholders' equity)
|
43.5%
|
26%
|
-
|
-
|
-4.98%
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
0.1700
|
0.2300
|
-
|
-
|
0.3000
|
-
|
-
|
-
|
Cash Flow per Share
|
0.1100
|
0.1100
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
2.36
|
12
|
12.8
|
1.86
|
1.32
|
4.99
|
5.23
|
5.54
|
Capex / Sales
|
1.4%
|
6.46%
|
7.06%
|
0.95%
|
0.59%
|
1.9%
|
1.74%
|
1.61%
|
Announcement Date
|
05/03/20
|
04/03/21
|
17/03/22
|
16/03/23
|
14/03/24
|
-
|
-
|
-
|
Average target price
2
EUR Spread / Average Target +122.22% Consensus |
1st Jan change
|
Capi.
|
---|
| -12.71% | 647M | | +25.83% | 661B | | +27.00% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +13.09% | 231B | | +5.46% | 200B | | -9.61% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|